Mr. Stephen Van Deventer reports

PREVECEUTICAL FILES CYCLIC PEPTIDES AND USES THEREOF IN THE EU AND AUSTRALIA

Preveceutical Medical Inc. is furthering the progress of cyclic peptides and uses thereof of its patent families.

Preveceutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021408143, and the European case has been allocated application no. EP21908152.8. This is in addition to patent applications having recently been filed in the US and Canada.

Preveceutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as we continue our clinical process.

Preveceutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "We continue to secure patents in all major jurisdictions globally to ensure our IP is well protected."

Although Preveceutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

About Preveceutical

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.

With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

We seek Safe Harbor.